Lipitor Trial To Study The Effect Of Torcetrpib/Atorvastatin To Atorvastatin Alone.
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00137462|
Recruitment Status : Completed
First Posted : August 29, 2005
Last Update Posted : November 16, 2007
The Torcetrapib project was terminated on December 2, 2006 due to safety findings.
To look at various lipids in the blood of people with Fredrickson Type IIa and Type IIb mixed dyslipidemias
|Condition or disease||Intervention/treatment||Phase|
|Hyperlipidemia||Drug: torcetrapib/atorvastatin Drug: atorvastatin||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||900 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||A Phase 3, Double-Blind, Randomized, Multisite Trial Of The Efficacy, Safety, And Tolerability Of The Fixed Combination Torcetrapib/Atorvastatin Administered Orally, Once Daily For 12 Months, Compared To Atorvastatin Alone, Titrated Based On NCEP ATP-III LDL-C Goals In Subjects With Fredrickson Types IIa And IIb Dyslipidemias|
|Study Start Date :||November 2004|
|Study Completion Date :||September 2006|
- Change in lipid parameters (HDL, LDL) at various timepoints over 12 months.
- Changes in levels of lipids and other biomarkers.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00137462
Show 59 Study Locations
|Study Director:||Pfizer CT.gov Call Center||Pfizer|